X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs DR. REDDYS LAB - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD DR. REDDYS LAB BIOCON LTD/
DR. REDDYS LAB
 
P/E (TTM) x 36.3 26.6 136.4% View Chart
P/BV x 4.8 2.7 175.9% View Chart
Dividend Yield % 1.5 1.0 148.4%  

Financials

 BIOCON LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
DR. REDDYS LAB
Mar-16
BIOCON LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs4964,383 11.3%   
Low Rs3972,750 14.4%   
Sales per share (Unadj.) Rs174.3920.1 18.9%  
Earnings per share (Unadj.) Rs44.8126.1 35.5%  
Cash flow per share (Unadj.) Rs56.9183.0 31.1%  
Dividends per share (Unadj.) Rs5.0020.00 25.0%  
Dividend yield (eoy) %1.10.6 199.9%  
Book value per share (Unadj.) Rs202.8685.8 29.6%  
Shares outstanding (eoy) m200.00170.61 117.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.63.9 66.0%   
Avg P/E ratio x10.028.3 35.2%  
P/CF ratio (eoy) x7.819.5 40.2%  
Price / Book Value ratio x2.25.2 42.3%  
Dividend payout %11.215.9 70.4%   
Avg Mkt Cap Rs m89,220608,481 14.7%   
No. of employees `0004.421.7 20.4%   
Total wages/salary Rs m6,36331,874 20.0%   
Avg. sales/employee Rs Th7,894.57,244.4 109.0%   
Avg. wages/employee Rs Th1,441.21,470.9 98.0%   
Avg. net profit/employee Rs Th2,029.7992.8 204.4%   
INCOME DATA
Net Sales Rs m34,854156,978 22.2%  
Other income Rs m8452,693 31.4%   
Total revenues Rs m35,699159,671 22.4%   
Gross profit Rs m8,20034,587 23.7%  
Depreciation Rs m2,4239,705 25.0%   
Interest Rs m102824 12.4%   
Profit before tax Rs m6,52026,751 24.4%   
Minority Interest Rs m-7440-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5,7540-   
Tax Rs m2,5695,237 49.1%   
Profit after tax Rs m8,96121,514 41.7%  
Gross profit margin %23.522.0 106.8%  
Effective tax rate %39.419.6 201.3%   
Net profit margin %25.713.7 187.6%  
BALANCE SHEET DATA
Current assets Rs m39,932118,201 33.8%   
Current liabilities Rs m16,27668,368 23.8%   
Net working cap to sales %67.931.7 213.8%  
Current ratio x2.51.7 141.9%  
Inventory Days Days5460 89.3%  
Debtors Days Days8697 88.9%  
Net fixed assets Rs m39,10172,265 54.1%   
Share capital Rs m1,000853 117.2%   
"Free" reserves Rs m38,591111,548 34.6%   
Net worth Rs m40,556117,009 34.7%   
Long term debt Rs m20,72410,690 193.9%   
Total assets Rs m84,816200,104 42.4%  
Interest coverage x64.933.5 194.0%   
Debt to equity ratio x0.50.1 559.3%  
Sales to assets ratio x0.40.8 52.4%   
Return on assets %10.711.2 95.7%  
Return on equity %22.118.4 120.2%  
Return on capital %19.021.6 87.9%  
Exports to sales %30.746.3 66.5%   
Imports to sales %20.49.0 227.8%   
Exports (fob) Rs m10,71772,618 14.8%   
Imports (cif) Rs m7,10514,050 50.6%   
Fx inflow Rs m11,78975,405 15.6%   
Fx outflow Rs m8,39327,115 31.0%   
Net fx Rs m3,39648,290 7.0%   
CASH FLOW
From Operations Rs m5,26440,476 13.0%  
From Investments Rs m-9,540-19,421 49.1%  
From Financial Activity Rs m10,867-17,009 -63.9%  
Net Cashflow Rs m6,5914,046 162.9%  

Share Holding

Indian Promoters % 40.4 25.5 158.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.4 155.6%  
FIIs % 10.7 35.3 30.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 19.9 15.3 130.1%  
Shareholders   109,995 75,885 144.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 21, 2017 03:37 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS